statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	416
SG - Singapore	195
RU - Federazione Russa	168
IT - Italia	123
VN - Vietnam	97
CN - Cina	77
BR - Brasile	40
HK - Hong Kong	40
DE - Germania	33
NL - Olanda	17
FR - Francia	16
IN - India	13
CI - Costa d'Avorio	11
CA - Canada	10
GB - Regno Unito	10
BD - Bangladesh	8
JP - Giappone	8
FI - Finlandia	7
IQ - Iraq	5
EC - Ecuador	4
UA - Ucraina	4
ZA - Sudafrica	4
AT - Austria	3
MX - Messico	3
PL - Polonia	3
SE - Svezia	3
AR - Argentina	2
ES - Italia	2
KR - Corea	2
TH - Thailandia	2
AF - Afghanistan, Repubblica islamica di	1
BE - Belgio	1
BN - Brunei Darussalam	1
BW - Botswana	1
BY - Bielorussia	1
CL - Cile	1
CO - Colombia	1
CZ - Repubblica Ceca	1
EG - Egitto	1
GR - Grecia	1
GT - Guatemala	1
ID - Indonesia	1
IE - Irlanda	1
IL - Israele	1
JO - Giordania	1
LA - Repubblica Popolare Democratica del Laos	1
LV - Lettonia	1
MA - Marocco	1
NP - Nepal	1
PA - Panama	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
PY - Paraguay	1
RO - Romania	1
SN - Senegal	1
TN - Tunisia	1
TR - Turchia	1
TW - Taiwan	1
UY - Uruguay	1
VE - Venezuela	1
Totale	1.357

Nome	#
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2	172
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells	147
Evidence that PP2A activity is dispensable for spindle assembly checkpoint-dependent control of Cdk1	143
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing	140
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling	137
Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC	135
Interactions of spike‐rbd of sars‐cov‐2 and platelet factor 4: New insights in the etiopathogenesis of thrombosis	134
Wee1 rather than plk1 is inhibited by AZD1775 at therapeutically relevant concentrations	131
Immunomodulatory mabs as tools to investigate on cis-interaction of pd-1/pd-l1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments	130
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells.	119
Totale	1.388

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	79	0	4	1	2	1	1	2	5	3	11	25	24
2022/2023	82	10	4	3	2	9	7	0	5	10	14	13	5
2023/2024	88	3	11	18	10	4	16	3	15	0	0	4	4
2024/2025	384	14	4	6	3	7	46	31	24	20	48	160	21
2025/2026	656	82	32	70	39	122	17	77	28	91	49	24	25
2026/2027	3	3	0	0	0	0	0	0	0	0	0	0	0
Totale													1.388